Abstract
DCs are recognized as the pivotal group of lymphocytes, which induce a variety of antitumor immune responses. Enduring professional antigen presenting cells, DCs eminence to induce adaptive antitumor immune response was exploited, which showed promising results in DCs-based phased clinical studies. Nevertheless, DCs also influence other immune cells to induce multiple arms of immune system to cure cancer. Recently, direct cytotoxic capacity of DCs has been demonstrated in several studies. Altogether DCs hold a strong link between innate and adaptive immune responses. DCs are known to kill tumor cells, phagocytose immunogenic substrates and present a wide variety of antigens to prime T cells to induce concerted antitumor responses. These functional aspects of DCs are dependent on the receptors that participate in the stimulation of DCs. In this review, we have discussed these receptors that are known to induce direct cytotoxicity as well as the receptors that greatly influence their antigen presentation functions. Thus DCs are turning out to be an important cell type in cancer immunotherapy.
Keywords: Dendritic cell receptors, antitumor response, apoptosis, tumor therapy
Current Molecular Medicine
Title: Dendritic Cells and their Receptors in Antitumor Immune Response
Volume: 9 Issue: 6
Author(s): Raghvendra M. Srivastava and Ashok Khar
Affiliation:
Keywords: Dendritic cell receptors, antitumor response, apoptosis, tumor therapy
Abstract: DCs are recognized as the pivotal group of lymphocytes, which induce a variety of antitumor immune responses. Enduring professional antigen presenting cells, DCs eminence to induce adaptive antitumor immune response was exploited, which showed promising results in DCs-based phased clinical studies. Nevertheless, DCs also influence other immune cells to induce multiple arms of immune system to cure cancer. Recently, direct cytotoxic capacity of DCs has been demonstrated in several studies. Altogether DCs hold a strong link between innate and adaptive immune responses. DCs are known to kill tumor cells, phagocytose immunogenic substrates and present a wide variety of antigens to prime T cells to induce concerted antitumor responses. These functional aspects of DCs are dependent on the receptors that participate in the stimulation of DCs. In this review, we have discussed these receptors that are known to induce direct cytotoxicity as well as the receptors that greatly influence their antigen presentation functions. Thus DCs are turning out to be an important cell type in cancer immunotherapy.
Export Options
About this article
Cite this article as:
Srivastava M. Raghvendra and Khar Ashok, Dendritic Cells and their Receptors in Antitumor Immune Response, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970715
DOI https://dx.doi.org/10.2174/156652409788970715 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design CRISPR/Cas9 Genome Editing Tool: A Promising Tool for Therapeutic Applications on Respiratory Diseases
Current Gene Therapy Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Oncogene Expression Modulation in Cancer Cell Lines by DNA G-Quadruplex-Interactive Small Molecules
Current Medicinal Chemistry Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Targeting Toll-Like Receptor Signaling Pathways for Design of Novel Immune Therapeutics
Current Drug Discovery Technologies Posttranscriptional Regulation of p53 and its Targets by RNABinding Proteins
Current Molecular Medicine Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy
Current Drug Delivery Interaction of Autophagy and Toll-Like Receptors: A Regulatory Cross- Talk - Even in Cancer Cells?
Current Drug Targets Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications
Current Medicinal Chemistry Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Live Yeast Cell Derivative Induces c-fos Expression in THP-1 Monocytes
Medicinal Chemistry Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Current Pharmaceutical Design Epigenetic Modification Restores Functional PR Expression in Endometrial Cancer Cells
Current Pharmaceutical Design Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
Current Drug Targets